Epigeneres Biotech, a Mumbai-based exclusive licensee in India of Singapore-based Tzar Labs, has raised USD 6 million in a Series B funding round led by Kotak Investment Advisors, Moez Daya (of Satya Capital), and LetsVenture Angel Fund on 18 January 2022.
Investors: The latest funding round was led by Kotak Investment Advisors, Moez Daya (Satya Capital), and LetsVenture Angel Fund. Other investors include Ashish Kacholia, East River Advisors, One Decacorn, Nandita Advisors, and Chockalingam Valliappa, to name a few.
The Objectives behind the funding: The company plans to deploy the current proceeds towards expanding its Lab facilities, scaling operations, develop new products and developing an AI platform to launch the service in India – a world first.
About Epigeneres Biotech
Founded in 2008 by Ashish Tripathi, Epigeneres is a leading biotechnology company that discovers, develops, manufactures, and commercialises molecular medicines and nutrigenomic formulations to treat and prevent severe medical conditions like cancer and diseases of ageing. It also has co-developed cancer prognostic and diagnostic technology with Singapore-based Tzar Labs and is the sole licensee in India for this technology. With a pioneering breakthrough in RNA bio-markers technology, the startup can even detect cancer in Stage Zero (i.e., before tumour formation). Epigeneres Biotech has V Krishnan (Promoter, Justdial) and Shailesh Haribhakti (BOD Torrent Pharma) as board members.
What the Founder has to say:
Ashish Tripathi, Founder & Chairman of Epigeneres, said, “This latest round of financing will help us continue our upward trajectory in early detection of cancer. The investment will go toward expanding the R&D team, scaling operations, and developing new products, even as we continue bringing out the finest healthcare technologies and solutions. We have received very positive feedback from the market, and with the help of our investors and the Government, we will soon begin to commercialise the cancer test; first in India, and then at a global level.”
What the Investors have to say:
Speaking on the funding, Nitin Deshmukh of Kotak said, “The ability to detect cancer through a simple blood test at Stage Zero can be a major breakthrough that can change the way cancer diagnosis is approached. We see this as an excellent opportunity to partner in the pioneering growth story of a home-grown Indian company that is innovating diagnostic technologies in oncology.”
“I am proud and excited to be backing this transformational early-detection technology, which will be a dramatic enabler in cancer detection, treatment and safer cancer drug development. I have a strong conviction that Epigeneres’ technology and research-backed approach is scalable, value-driven, performance backed, and a remarkable investor opportunity,” said Moez Daya, a founder and partner at Satya Capital, Founder and ex CEO of Celtel International.
Nimesh Kampani, who led the round on LetsVenture, said, “We believe that the Epigeneres Biotech offering will transform the way cancer care is delivered with real-time, comprehensive and swift insights, something never experienced before in India or the world. We see tremendous potential and are excited to back the Company in its accelerated growth.
For more extensive analysis and Market Intelligence reports feel free to approach us or visit our website: Venture Capital Market Intelligence Reports | VCBay.
We try our 2022 best to fact-check and bring the best, well-researched, and non-plagiarized content to you. Please let us know
-if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback and thank you for stopping by!
Next Article
, and LetsVenture Angel Fund on 18 January 2022.){kind=link}